ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2019
Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Psychometric properties of the EQ-5D-5L: a systematic review of the literature.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.Health technology assessment (Winchester, England) · 2021Pooled it
- Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review.Frontiers in public health · 2021Pooled it
- Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Trial
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.United European gastroenterology journal · 2023Trial
- Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.Health and quality of life outcomes · 2020Trial
- Is EQ-5D-5L better than EQ-5D-3L? A comparison of descriptive systems and utility scores in patients with kidney chronic disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Comparing the measurement properties of the EQ-5D-Y-3L and EQ-5D-3L in a general population sample of adults.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: A UK cross-sectional survey.United European gastroenterology journal · 2025Article
- The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Quality of life of inflammatory bowel diseases patients in france with EQ-5D-5 L: the QALY-MICI study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Population-level norm values by EQ-5D-3L in Hungary - a comparison of survey results from 2022 with those from 2000.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Article
- Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.PharmacoEconomics · 2024Article
- Construct validity of EQ-5D-5L among patients with inflammatory bowel disease-a study based on real-world data from the Swedish Inflammatory Bowel Disease Registry.Journal of patient-reported outcomes · 2024Article
- A head-to-head comparison of the measurement properties of EQ-5D-3L and EQ-5D-5L in Chinese family caregivers of cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Assessment of health-related quality of life and its determinants among COVID-19 intensive care unit survivors.Journal of family medicine and primary care · 2023Article
- Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn's perianal fistulas.World journal of gastrointestinal surgery · 2023Article
- Evaluation of the EQ-5D-5L, EQ-VAS stand-alone component and Oxford knee score in the Australian knee arthroplasty population utilising minimally important difference, concurrent validity, predictive validity and responsiveness.Health and quality of life outcomes · 2023Article
- The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease.Crohn's & colitis 360 · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn's disease (CD). We aimed to compare the measurement properties of the two adult versions of EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with CD.
methodsBetween 2016 and 2017, a multicentre cross-sectional survey was carried out. Consecutive outpatients with CD completed the 3L, 5L and EQ visual analogue scale (VAS). Disease severity was graded by the Crohn's Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI). The 3L and 5L were compared in terms of feasibility, agreement, ceiling effect, redistribution properties, discriminatory power, convergent and known-groups validity.
resultsTwo-hundred and six patients (54.9% male, mean age 35 ± 11 years) participated in the survey. For 3L, 25 unique health states were observed versus 59 for the 5L. The overall ceiling effect decreased from 29.6% (3L) to 25.5% (5L). Absolute discriminatory power improved (mean Shannon index 0.84 vs. 1.18). The 3L correlated stronger with EQ VAS and CDAI scores, whereas the 5L with PDAI. The 5L demonstrated a better known-groups validity on the basis of age, perianal fistulas, extraintestinal manifestations and disability.
conclusionsThis is the first study to report the impact of CD on quality of life using the EQ-5D-5L questionnaire. The 5L seems to perform better than 3L in terms of feasibility, ceiling effect, discriminatory power and known-groups validity. Understanding the differences in psychometrics between the 3L and 5L is essential as they have substantial implications for financial decision-making about CD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.